Background: Thoracic endovascular aortic repair (TEVAR) for thoracic aortic aneurysms (TAAs) is in rapid expansion due to its minimal invasiveness. However, TEVAR for an arch aneurysm with a straight stent graft needs surgical reconstruction for supra-aortic vessels. A branched stent graft pioneered by Inoue (branched Inoue Stent Graft [ISG]) has been expected to resolve this problem, but its utility remains to be established in the real clinical setting. This study evaluated the long-term clinical outcome of branched ISGs for TAAs.
Thoracic endovascular aortic repair (TEVAR) for thoracic aortic aneurysms (TAAs) is in rapid expansion because it is less invasive. Recent reports indicate the feasibility of TEVAR for TAA in various clinical conditions. [1] [2] [3] [4] [5] [6] [7] TAA of the descending aorta is a good indication for TEVAR with the straight stent grafts that are now commercially available. However, patients with an arch aneurysm that involves the supra-aortic vessels need conventional open repair. Extra-anatomical surgical bypass for those vessels, which is called debranched-TEVAR (dTEVAR), [8] [9] [10] [11] or complex endovascular procedures, such as chimney technique 12, 13 or in situ fenestration, 14 are needed to preserve neck vessels for TEVAR with a straight stent graft. Although dTEVAR is less invasive than conventional open arch replacement, mortality and morbidity are higher, 8, 9, 11 and sometimes it is difficult to perform for complicated patients because of old age or severe comorbidities.
To resolve these problems straightforwardly, Inoue devised a branched stent graft of unibody construction, the branched Inoue Stent Graft (ISG), that allows repair of arch aneurysm without extra-anatomical surgical reconstruction or a complex endovascular procedure. [15] [16] [17] [18] Saito et al 17 have reported short-to midterm feasibility of TEVAR with the single-branched ISG. 17 However, long-term clinical follow-up with larger numbers of patients is still unclear. This study evaluated the long-term clinical outcomes of TEVAR with the branched ISG for arch aneurysms.
METHODS

Study population
This study was a physician-initiated, noncompany sponsored, prospective registry of the ISG in Kyoto University Hospital. The study protocol was approved by the Kyoto University Graduate School of Medicine Ethics Committee, and all participants gave written informed consent. The study was registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000005430). From March 2003 to December 2013, 217 consecutive patients with TAA or aortic dissection underwent TEVAR with the ISG. Straight ISGs were used in 74 patients, abdominal branched ISGs in 13, and thoracic branched ISGs in 130. Among the 130 patients with the branched ISG, 32 were excluded from the present analysis because they constituted an etiologically distinctive cohort that had aortic dissection (n ¼ 31) or a patent ductus arteriosus (n ¼ 1). Nine patients were excluded because of a secondary TEVAR after the primary procedure (n ¼ 7) or an additional TEVAR after surgical replacement of the proximal aortic arch (n ¼ 2) (Fig 1) . This study included 89 patients (single branch, n ¼ 64; double branch, n ¼ 18; triple branch, n ¼ 7) who underwent TEVAR with a branched ISG for TAA.
Study device and implant procedure: branched ISG
Study device. The ISGs were produced by PTMC Institute, Kyoto, Japan. They were made according to three-dimensional structural models generated on the computer from computed tomography (CT) images of TAAs. To this end, we have developed specialized software to design an optimized stent graft for each patient. The branched ISG is a custom-made all-in-one stent graft consisting of an aortic trunk section and branch sections which were sewn together (Figs 2 and 3; Supplementary Fig 1, online only) . The main body and branch section of the ISG are constructed with a woven Dacron (DuPont, Wilmington, Del) polyester graft on which extra flexible nickel titanium rings are put for reinforcement and self-expandability. Further, small Dacron cuffs are attached to the proximal and distal edges of the graft to make the sealing between the graft and aortic inner wall tighter and less invasive. The main body and branch section were prepared separately from two series of Dacron grafts with varying diameters in 2-mm increments from 18 to 46 mm and from 8 to 20 mm, respectively. Then, they were sewn together in the appropriate combination and geometry. The branches in double-and triple-branched devices were attached specially based on the distance apart and axial location of the target vessels as predetermined by the computeraided design system.
Selection criteria and contraindications. The singlebranched graft requires a proximal landing zone that retains two margins of at least 5 mm in their total length being located on both sides of the left subclavian artery (LSCA) so that at least one cuffed sealing ring can be securely placed therein. Similarly, the double-branched graft requires a bipartite proximal landing zone sized at least 5 mm in total and located on both sides of the left common carotid artery (LCCA) (Fig 2, A and B) . The triplebranched graft requires at least 20 mm proximal to the brachiocephalic artery. The acceptable range of diameters in the aorta and the branch vessels is 16 to 42 mm for the main graft and 7 to 18 mm for the branched grafts. In either type of branched graft, therefore, an enlarged aorta >42 mm in diameter at the proximal landing zone is contraindicated.
Implant procedure. wires. The main body and branch are individually constricted using a thread and a 0.020-mm nickel titanium wire in such a way that the stent graft does not spontaneously expand after its release from the sheath. The common femoral artery was surgically isolated with local, epidural, or general anesthesia. After administration of 8000 to 10,000 U of unfractionated heparin, a 20F to 24F (single branch, 20F-22F; double branches, 22F-24F; triple branches, 24F) ISG original introducer sheath was inserted through the common femoral artery and advanced to the descending thoracic aorta. The ISG system in the folded form was introduced into the sheath, released from the sheath at the descending thoracic aorta, and advanced to the aortic arch.
In the case of a single-branched ISG, a 7F sheath was inserted from the left brachial artery. The free end of a traction wire attached to the tip of the LSCA branch section was caught by a gooseneck snare introduced through the 7F guiding catheter. The traction wire of the branch section was pulled into the LSCA to fix the branched section ( Supplementary Fig 2, online only). In the case of a double-branched graft, the LCCA was percutaneously punctured with a 5F sheath to catch the traction wire of LCCA branch section. The traction wires attached to branch sections were pulled into the LCCA and LSCA, respectively. In a similar way, in the case of a triplebranched graft, a 7F sheath was inserted from the right brachial artery. The traction wire of the innominate artery branch was caught by a gooseneck snare introduced through the 7F guiding catheter from the right brachial artery. Each traction wire attached to the three branch sections was pulled into the innominate artery, LCCA, and LSCA, respectively ( Supplementary Fig 3, online only) .
After the ISG was fixed in place, the constricted ISG was deployed by removing the wire with rapid right ventricular pacing support. After deployment of ISG, touch-up balloon was performed with rapid right ventricular pacing support. 
Data collection and follow-up
Demographic, angiographic, and procedural data were collected from hospital records. Baseline clinical characteristics, such as hypertension, dyslipidemia, current/past smoking, hemodialysis, malignancy, ischemic heart disease, chronic obstructive pulmonary disease (COPD), and previous thoracotomy due to heart or lung disease, were regarded as present when these diagnoses were recorded in the hospital records. Diabetes was defined as treatment with oral hypoglycemic agents or insulin, or both, prior clinical diagnosis of diabetes, glycated hemoglobin level >6.5%, or blood glucose level >200 mg/dL. Cerebrovascular disease included ischemic or hemorrhagic stroke and was defined as stroke with neurologic symptoms lasting >24 hours. Left ventricular ejection fraction was measured by echocardiography or left ventriculography. Chronic renal disease was defined as an estimated glomerular filtration rate of <30 mL/min/1.73 m 2 . Baseline medications were collected from hospital records during the index hospitalization.
All patients were monitored with contrast-enhanced CT #1 month after the procedure. CT follow-up imaging was then repeated at 6 months and every subsequent year. Clinical follow-up information was collected through contact with patients at the outpatient department or by telephone.
End points
The primary end point was freedom from aneurysmrelated death, which was defined as death caused by aneurysm rupture or death that may have resulted from the primary or secondary treatment of the TAA. Secondary end points were any periprocedural adverse events, changes of aneurysm diameter, stroke, any repeat endovascular intervention, and freedom from all-cause death and major adverse event (MAE). MAE was defined as a composite of aneurysm-related death, surgical conversion, aneurysm rapture, persistent type I or III endoleak, graft infection, stent graft occlusion, graft migration, and aneurysm expansion of >5 mm. Sudden cardiac death was defined sudden death without persistent endoleak and sac enlargement. Respiratory disorder death was defined as death from pneumonia, COPD, or interstitial pneumonia. Cerebrovascular death was defined death from hemorrhagic or ischemic stroke. Vascular death was defined death from renal failure, occlusion of a visceral artery, or rupture of abdominal aortic aneurysm. Deployment success of the branched ISG was defined as implantation of ISG device at the planned position with cannulation of all vessels as intended, without surgical conversion or death.
Statistical analysis
Continuous variables are expressed as the mean 6 standard deviation or median and interquartile range and were compared using the Student t-test or the Wilcoxon rank sum test according to their distribution. Categoric variables are presented as numbers and percentages. The cumulative incidence of clinical events was estimated by the Kaplan-Meier method. Statistical analysis was conducted by two physicians (J.T., H.H) with the use of JMP 10.0 software (SAS Institute Inc, Cary, NC). All the statistical analyses were two-tailed, and P values of <.05 were considered statistically significant.
RESULTS
Patient characteristics. Mean aneurysm diameter was 61.1 6 12 mm, and mean age was 76.8 6 8.7 years. TAA patients had frequent comorbidities associated with atherosclerosis, such as ischemic heart disease (43%) and cerebrovascular disease (26%). COPD was present in 34% of TAA patients because of frequent smoking history (62%) ( Table I) . Half of patients took antiplatelet medications (aspirin, 44%; thienopyridine, 8.9%) at discharge for treatment of other atherosclerotic diseases, such as ischemic heart disease or cerebrovascular disease, to prevent other vascular events or maintain graft patency. Even though patients with aortic aneurysm had advanced atherosclerosis, the rate of statin use was rather low (48%) ( Table I) . Procedure details and periprocedural outcomes. All deployments of branched ISGs were successful. The covered length of aorta ranged from 80 to 330 mm at the index procedure, and three patients needed an additional straight graft. Mean procedure time was 172 6 96 minutes and was longer in multiple branched ISGs (single branch, 137 6 61 minutes; double branch, 201 6 53 minutes; and triple branch, 408 6 86 minutes). Contrast volume was 260 6 102 mL, and median hospital stay was 17 days (Table II) . Note that the hospital stay in Japan tends to be longer under a generous medical insurance support than in other countries.
All patients underwent TEVAR through a femoral artery with cutdown. The TEVAR was performed with local anesthesia in 48% of patients and with epidural anesthesia in 42%. Only nine patients underwent TEVAR with general anesthesia.
The 30-day mortality was 4.5% (4 patients) in all branched ISGs (Table III) . Causes of death were systemic embolization, respiratory failure, thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation. The incidence of stroke was 16% (14 patients) and was higher in multiple-branched ISGs (single branch, 5 patients [7.8%]; double branch, 6 patients [33%]; triple branch, 3 patients [42%]). Two of three perioperative deaths in patients with triple-branched ISGs were caused by fatal stroke associated with systemic embolization. The other death was caused by intracranial hemorrhage because of consumption coagulopathy after TEVAR for an aneurysm with a large diameter (75 mm).
Aortic dissection occurred in two patients because the touch-up balloon was oversized, as judged from a comparison of angiograms taken before and after the ballooning. Paraplegia occurred in one patient with a distal arch TAA treated with a single-branched ISG. Transfusion was needed in 12 patients (14%), all with branched grafts, during the procedure and perioperative period. An access route injury to the iliac artery occurred in 11 patients (12%). Most of the injuries were only dissection of the iliac artery and were treated with bare-metal stent implantation. Only one patient needed stent graft implantation to the iliac artery.
Long-term clinical outcomes. Median follow-up interval was 1345 (interquartile range, 683-2144) days. Freedom from aneurysm-related death during follow-up was 93% at 1 year and 93% at 5 years (Fig 4) . The six aneurysmrelated deaths were periprocedural deaths at the index TEVAR (Table IV) .
Freedom from all-cause death was 85% at 1 year and 59% at 5 years (Fig 4) . The causes of death are reported in Table IV . Most of deaths after TEVAR were of nonaneurysm-related causes, such as sudden cardiac death, respiratory disorder, cerebrovascular disease, malignancy, or infection. The cumulative incidence of ischemic stroke, with exception of periprocedural stroke, was 11% (5 patients) at 5 years. Two patients were critical: one sustained multiple strokes 3 years after single-branched ISG implantation, and the other sustained a stroke in the right hemisphere 4 years after (14) 8 (13) 3 (17) 1 (14) Systemic embolization 2 (2.2) 0 0 2 (14)
Access injury 11 (12) 9 (14) 0 2 (29) single-branched ISG implantation. Neither death was related to the implanted branch section. Except for the six periprocedural deaths, aneurysm diameter shrinkage of >5 mm was observed in 27 patients (33%), and the diameter was not changed in 48 (58%). The diameter enlarged >5 mm in eight patients (9%). Seven of these eight enlargements were caused by type I endoleak; however, sac enlargement was observed in one patient without definite type I endoleak.
The cumulative incidence of MAE was 24% at 5 years (Fig 5, A) . Persistent type I endoleak after the index TEVAR was observed in nine patients (double-branched ISG in 1, single-branched ISG in 8) (Table V) . Two patients underwent open repair directly. One patient underwent open repair shortly after the index TEVAR because of type I endoleak, and the other occurred 4 years after the index TEVAR because of proximal ring migration. Five patients underwent additional TEVAR for type I endoleak. Four patients were treated with an additional stent graft (1 double-branched graft, 1 single-branched graft, and 2 straight grafts) at the proximal portion due to type Ia endoleak, and one patient was treated with an additional stent graft at the distal portion due to a type Ib endoleak. However, type I endoleak was still observed in four patients, and one underwent open repair. The remaining two patients with type I endoleak declined additional invasive treatment because of their general status (Supplementary Table, 
online only).
Graft infection occurred in one patient and was successfully treated with antibiotic therapy. Among the 89 patients enrolled in this study, a branch graft occlusion was observed at the LSCA during the follow-up period in a patient who received a double-branched graft. That patient did not undergo an additional intervention because the patient had no symptoms of arm claudication or stroke.
The cumulative incidence of additional endovascular therapy was 8.2% (6 patients) at 5 years (Fig 5, B) . Five procedures were additional TEVAR, and one was an endovascular repair for iliac artery injury.
DISCUSSION
This is the first study to evaluate the long-term outcomes of TEVAR with branched ISGs. The main findings of this study were as follows:
First, periprocedural outcome of TEVAR with singlebranched ISG was acceptable. However, TEVAR with multibranched ISG needs more improvement to reduce the incidence of periprocedural stroke.
Second, TEVAR with branched ISG demonstrates a favorable long-term outcome with a low incidence of aneurysm-related death and a low incidence of branch graft occlusion.
All branched ISG were successfully deployed at the planned position. Especially in cases of single-branched ISG, procedure time (137 6 61 minutes) and Kaplan-Meier curves for aneurysm-related death and all-cause death. The estimated event-free survival of aneurysm-related death and standard error was 93% 6 2.7% at 1 year, 93% 6 2.7% at 2 years, 93% 6 2.7% at 3 years, 93% 6 2.7% at 4 years, and 93% 6 2.7% at 5 years. The estimated event-free survival of all-cause death and standard error was 85% 6 3.8% at 1 year, 77% 6 4.5% at 2 years, 70% 6 5.0% at 3 years, 62% 6 5.4% at 4 years, and 59% 6 5.6% at 5 years. Compared with these straight stent grafts, the singlebranched ISG does not require additional complicated procedures and can be performed with low perioperative risk. However, mortality and incidence of stroke were higher in TEVAR with multibranched ISGs. The high incidence of stroke or systemic embolization was associated with the high mortality rate of the multibranched ISG system. In cases of stroke or systemic embolization, CT revealed a more or less shaggy image at the aortic arch (Supplementary Fig 4, online only) . Multiple embolizations might have occurred during the delivery procedure of the ISG system through the aortic arch or the catching procedure of the branch section at the diseased arch section with longer procedure time. Percutaneous puncture of the LCCA with the 5F sheath in multibranched ISGs might be another factor.
In addition, the proximal landing zone was zone 0 for the triple-branched ISG and was zone 1 for the doublebranched ISG. 22 Recent reports of dTEVAR suggested that landing on zone 0 and 1 is associated with higher mortality and an increased incidence of periprocedural stroke than when landing on zone 2. 9,11 The poor outcomes observed with multibranched ISGs might be associated not only with the more complex procedure but also with the broader ranges of diseased aorta and the more proximally located landing zone than neck vessels. The procedure for TEVAR with multibranched ISGs needs to be simplified and improved to minimize periprocedural adverse events. Thus, we are still working to construct an improved branched ISG system with a lower profile, smoother surface, and greater flexibility by which to reduce frictional contacts with the atherosclerotic wall of aorta during ISG implantation.
Long-term outcome of branched ISG was also acceptable. On the one hand, the cumulative incidence of aneurysm-related death was low (6.8%) at 5 years. On the other hand, the cumulative incidence of all-cause death was very high (41%) at 5 years. These results are consistent with other studies. 2, 22, 23 We note that candidates for treatment with the branched ISG were diagnosed to be at high risk for open repair because of advanced age or multiple comorbidities associated with atherosclerotic disease, or both. Therefore, most patients died of nonaneurysm-related causes, such as Fig 5. A, Kaplan-Meier curve for major adverse event (MAE), defined as aortic disease-related death, surgical conversion, aneurysm rupture, persistent type I or III endoleak, infection of stent graft, stent graft occlusion, and migration or >5 mm expansion of maximum diameter. The estimated event-free survival of MAE and standard error was 85% 6 3.8% at 1 year, 85% 6 3.8% at 2 years, 85% 6 3.8% at 3 years, 79% 6 4.4% at 4 years, and 76% 6 5.5% at 5 years. B, Kaplan-Meier curve for incidence of additional endovascular repair. The estimated event-free survival of additional endovascular repair and standard error was 95% 6 2.4% at 1 year, 94% 6 2.7% at 2 years, 92% 6 3.3% at 3 years, 92% 6 3.3% at 4 years, and 92% 6 3.3% at 5 years. sudden cardiac death and cerebrovascular disease (Table IV) . Respiratory disorder was also major cause of death in this study because there were many patients with a smoking habit or COPD. The cumulative incidence of stroke (11% at 5 years) was similar with previous reports in ischemic heart disease patients with aortic disease (12% at 5 years). 24 That indicates the branched ISG graft design and graft materials were not associated with the long-term incidence of stroke. MAE at the late phase of follow-up was mainly driven by surgical conversion resulting from persistent type I endoleak and continual aneurysm expansion (Table IV; Supplementary Table, online only). The incidence of additional TEVAR and surgical conversion was not as high compared with other studies 2 and was better than TEVAR with fenestrated stent grafts. 25 The patients in this study did not experience late-phase aortic dissection at the edge of the ISG because the extra-flexible nickel titanium ring is supposed to help minimize potential damage to the aortic intima. Occlusion of the branched section occurred in only one patient at the LSCA graft. In endovascular repair of abdominal aortic aneurysm, the incidence of limb stenosis or occlusion was reported to be as high as 3% to 7%. 26, 27 The branch section of the ISG was reinforced by nitinol rings in the same way as the main body. The branch graft of the ISG is resistant to kinking owing to its flexible structure. Graft patency could be further supported by antiplatelet therapy (aspirin, 44%; thienopyridine, 8.9%) for treatment of concomitant disease or to maintain graft patency. The rapid blood flow through the arch segment might be associated good graft patency.
The present study has several limitations. First, this was a single-arm observational study of an original device. This study did not have a control group treated with dTE-VAR or surgical aortic arch replacement. Second, the study population was relatively small in number.
CONCLUSIONS
Periprocedural outcomes of single-branched ISG for TAAs were acceptable, and long-term safety and efficacy were demonstrated. However, procedural complications of the multibranched ISG leave room for improvement. This study should serve as landmark for TEVAR with branched graft for arch aneurysm.
